AI assistant
AVECHO BIOTECHNOLOGY LIMITED — Director's Dealing 2013
Apr 7, 2013
64468_rns_2013-04-07_88a114a9-4cf4-49c4-88d3-f4f5cd02367e.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [113 x 86] intentionally omitted <==
ASX Limited Market Announcements Office 5 April 2013
Phosphagenics Limited
Change of Director’s Interest Notice
Attached is an Appendix 3Y Notice covering the change in the entitlement of Mr S B James to non-quoted options (POHAU) which expired on 31 March 2013 and which were not exercised.
Ends
Enquiries: Mourice Garbutt Company Secretary Phosphagenics Limited +61 3 9605 5917
About Phosphagenics
Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM[®] – Targeted Penetration Matrix technology. TPM[®] is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.
The lead product advancing through clinical trials is an oxycodone and oxymorphone matrix system for the relief of chronic pain.
Phosphagenics’ shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).
www.phosphagenics.com www.elixia.com.au
Phosphagenics Limited ACN 056 482 403 ABN 32 056 482 403
11 Duerdin Street, Clayton VIC 3168 PO Box 1415, Clayton South MDC VIC 3169 Australia Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151
Web: www.phosphagenics.com Email: [email protected]
Page 1 of 1